CG Oncology, Inc. CGON
67.15
(1.61)
(2.34%)
as of 25 Sep
- Market cap
- $6.1B
- P/E
- 0.0×
Follow CGON
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1,394.08 | 713.89 | 1,116.58 | 1,006.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(79.46) | (88.62) | (100.46) | (135.02) | |
P/B ratio |
4.49 | 4.26 | 5.24 | 6.09 | |
Price to Tangible BV |
4.59 | 4.33 | 5.29 | 6.15 | |
EV/Sales |
1,092.64 | 551.48 | 908.84 | 843.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(20.74) | (18.73) | (29.10) | (29.42) | |
EV/FCF |
(20.68) | (18.72) | (29.02) | (29.28) | |
Quick Ratio |
22.30 | 24.09 | 30.60 | 21.78 | |
Current Ratio |
22.79 | 24.63 | 31.30 | 22.22 | |
Net Debt/EBITDA |
12.86 | 15.76 | 16.80 | 11.76 | |
Debt/Assets |
0.41% | 0.38% | 0.26% | 0.28% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.89 | 0.88 | 0.95 | 0.59 | |
Capex/Depreciation |
0.06 | 0.00 | (0.12) | 0.57 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,673.71% | 1,290.22% | 4,037.86% | 4,724.03% | |
Selling, General and Administrative Expense of Revenue |
1,400.60% | 774.89% | 1,918.74% | 2,504.41% | |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
440.04% | 309.52% | 597.78% | 1,238.89% | |
Graham Net Nets |
0.21 | 0.22 | 0.19 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.06%) | (4.99%) | (3.44%) | (3.79%) | |
Free Cash Flow Yield |
(3.79%) | (4.13%) | (2.80%) | (2.86%) | |
Revenue per Share |
0.02 | 0.03 | 0.01 | 0.01 | |
Operating CF per Share |
(0.51) | (0.47) | (0.67) | (0.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.51) | (0.47) | (0.68) | (0.53) | |
Cash per Share |
8.87 | 9.60 | 12.73 | 11.66 | |
Shareholders Equity per Share |
8.96 | 9.74 | 12.92 | 11.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.96 | 9.74 | 12.92 | 11.67 | |
Free Cash Flow |
(38.99) | (36.22) | (57.25) | (46.88) | |
Working Capital |
665.26 | 728.64 | 1,066.93 | 1,002.41 | |
Capital Expenditures |
(0.10) | (0.01) | (0.30) | (0.47) | |
Net Current Asset Value |
653.52 | 720.49 | 1,058.66 | 993.11 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.00 | 0.28 | 0.40 | |
Net Profit Margin |
(2,629.53%) | (1,779.03%) | (5,558.82%) | (6,832.84%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.33 | 0.73 | 0.81 | 0.49 | |
Average Payables |
6.63 | 6.12 | 7.48 | 9.93 | |
Average Assets |
641.19 | 773.19 | 931.72 | 893.55 | |
Average Common Equity |
612.21 | 742.99 | 898.27 | 849.74 |
Columns are period end dates